331 related articles for article (PubMed ID: 8465420)
1. Cytokine-release syndrome: differences between high and low doses of OKT3.
Norman DJ; Kimball JA; Barry JM
Transplant Proc; 1993 Apr; 25(2 Suppl 1):35-8. PubMed ID: 8465420
[No Abstract] [Full Text] [Related]
2. Five-year experience with a triple drug protocol in renal transplantation.
Pallardó LM; Sánchez J; García J; Puig N; Sánchez P; Górriz JL; Cruz JM
Transplant Proc; 1992 Feb; 24(1):56-7. PubMed ID: 1539342
[No Abstract] [Full Text] [Related]
3. Prophylactic OKT3, CyA, and steroids versus antilymphoblast globulin, CyA, and steroids in cadaveric kidney transplantation.
Griñó JM; Castelao AM; Serón D; Gonzalez C; Galceran JM; Gil-Vernet S; Andrés E; Bover J; Torras J; Alsina J
Transplant Proc; 1992 Feb; 24(1):39-41. PubMed ID: 1539329
[No Abstract] [Full Text] [Related]
4. Renal allograft rejection in a patient with the Wiskott-Aldrich syndrome.
Meisels IS; Strom TB; Roy-Chaudhury P; Abrams J; Shapiro ME
Transplantation; 1995 Apr; 59(8):1214-5. PubMed ID: 7732568
[No Abstract] [Full Text] [Related]
5. Is the routine use of induction immunosuppression with ALG or OKT3 justified in cadaveric renal transplantation?
Mozes MF; Venkat KK; Kupin W; Dumler F; Gracida C; Uniewski M; Anaise D; Tang DH
Transplant Proc; 1993 Feb; 25(1 Pt 1):575-6. PubMed ID: 8438420
[No Abstract] [Full Text] [Related]
6. Late acute rejection in renal transplant recipients: response to steroid treatment.
Prieto C; Pulido F; Rodríguez-Paternina E; Algranati C; Bello I; Farias J; G-Millet V
Transplant Proc; 1992 Feb; 24(1):35-6. PubMed ID: 1539312
[No Abstract] [Full Text] [Related]
7. Prospective trial of OKT3 for early prophylaxis of rejection in immunologic "high risk" renal transplant recipients: long-term results.
Pomer S; Waldherr R; Möhring K; Kempter F; Wiesel M; Weimer R
Transplant Proc; 1992 Oct; 24(5):1732-3. PubMed ID: 1412815
[No Abstract] [Full Text] [Related]
8. Does acute tubular necrosis affect renal transplant outcome? The impact of rejection episodes.
Troppmann C; Almond PS; Payne WD; Dunn DL; Gores PF; Gruessner RW; Sutherland DE; Matas AJ; Najarian JS
Transplant Proc; 1993 Feb; 25(1 Pt 2):905. PubMed ID: 8442263
[No Abstract] [Full Text] [Related]
9. Renal transplant artery thrombosis following treatment of allograft rejection with monoclonal anti-CD3 antibodies (OKT3).
Noël C; Hazzan M; Coppin MC; Pruvot FR; Bridoux F; Lelièvre G
Transplant Proc; 1995 Aug; 27(4):2438-9. PubMed ID: 7652870
[No Abstract] [Full Text] [Related]
10. Prophylaxis with a short course of OKT3 in renal transplantation: comparative analysis with recipients treated either with prophylactic ATG or with CyA.
Lloveras J; Puig JM; Oliveras A; Orfila A; Comerma I; Aubia J; Masramón J
Transplant Proc; 1992 Feb; 24(1):43-4. PubMed ID: 1539335
[No Abstract] [Full Text] [Related]
11. Comparison of OKT3 and antithymocyte globulin as induction immunosuppressive agents in renal transplantation.
Kitabayashi K; Munn SR; Sterioff S
Transplant Proc; 1996 Jun; 28(3):1973-5. PubMed ID: 8658964
[No Abstract] [Full Text] [Related]
12. Triple drug maintenance therapy in renal transplantation.
Pallardó LM; Sánchez J; Hernandez M; Górriz JL; Sánchez P; Beneyto I; Rochera A
Transplant Proc; 1992 Feb; 24(1):58-9. PubMed ID: 1539343
[No Abstract] [Full Text] [Related]
13. Effect of HLA matching and T- and B-cell crossmatch on acute rejection and graft survival following liver transplantation.
Chen M; Wade J; Levy GA; Greig PD
Transplant Proc; 1994 Oct; 26(5):2695-6. PubMed ID: 7940844
[No Abstract] [Full Text] [Related]
14. OKT3 first-line treatment of acute rejection episodes following combined pancreas and kidney transplantation.
Cantarovich D; Hourmant M; Dantal J; Giral M; Paineau J; Karam G; Soulillou JP
Transplant Proc; 1994 Apr; 26(2):549. PubMed ID: 8171548
[No Abstract] [Full Text] [Related]
15. Encephalopathy following the use of OKT3 in renal allograft transplantation.
Shihab FS; Barry JM; Norman DJ
Transplant Proc; 1993 Apr; 25(2 Suppl 1):31-4. PubMed ID: 8465419
[No Abstract] [Full Text] [Related]
16. Monitoring of donor sensitization in kidney transplant recipients by flow cytometric crossmatch.
Cinti P; Bachetoni A; Baiano V; Pretagostini R; Poli L; Berloco P; Renna Molajoni E; Cortesini R
Transplant Proc; 1993 Dec; 25(6):3265-6. PubMed ID: 8266536
[No Abstract] [Full Text] [Related]
17. Low-dose OKT3 induction therapy following renal transplantation leads to improved graft function and decreased adverse effects.
Brown M; Korb S; Light JA; Light T; Jonsson J; Aquino A
Transplant Proc; 1993 Feb; 25(1 Pt 1):553-5. PubMed ID: 8438411
[No Abstract] [Full Text] [Related]
18. Treatment of steroid-resistant and recurrent acute cardiac transplant rejection with a short course of antibody therapy.
Cantarovich M; Latter DA; Loertscher R
Clin Transplant; 1997 Aug; 11(4):316-21. PubMed ID: 9267721
[TBL] [Abstract][Full Text] [Related]
19. Clinical results of quadruple drug immunosuppression in liver transplantation.
Fabregat J; Fradera R; Jaurrieta E; Figueras J; Rafecas A; Rufi G; Casanovas T; Casais L; Gil Vernet S
Transplant Proc; 1992 Feb; 24(1):148-9. PubMed ID: 1539217
[No Abstract] [Full Text] [Related]
20. How successful is OKT3 rescue therapy for steroid-resistant acute rejection episodes after heart transplantation?
Wagner FM; Reichenspurner H; Uberfuhr P; Kur F; Kaulbach HG; Meiser BM; Ziegler U; Reichart B
J Heart Lung Transplant; 1994; 13(3):438-42; discussion 442-3. PubMed ID: 8061020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
